Valuation: Acrux Limited

Market Cap 6.16M 4.29M 3.78M 3.51M 3.23M 6.05M 416M 41.95M 16.36M 203M 16.12M 15.77M 704M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 8.93M 6.23M 5.48M 5.09M 4.68M 8.77M 603M 60.83M 23.73M 294M 23.37M 22.87M 1.02B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 month-14.29%
3 months+9.09%
6 months-14.29%
Current year-20.00%
1 week 0.01
Extreme 0.011
0.01
1 month 0.01
Extreme 0.011
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 2025-05-31
Director of Finance/CFO - 2021-06-20
Chief Tech/Sci/R&D Officer - 2015-02-14
Director TitleAgeSince
Chairman 74 2005-12-31
Director/Board Member - 2013-09-30
Director/Board Member 70 2016-05-31
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-40.00%-76.00% 4.29M
-0.66%+0.44%+14.72%+76.40% 48.41B
+2.20%+1.41%+61.04%+111.43% 34.99B
+1.26%-0.57%-5.20%+34.48% 11.62B
-0.46%-3.06%+14.15%+80.63% 11.47B
-1.12%-0.19%+36.83%+136.73% 8.99B
+1.52%+0.39%+48.79%-5.82% 6.88B
-0.09%-2.84%+13.23%+30.57% 6.62B
-0.59%-1.95%+2.23%+178.07% 6.43B
+1.60%-15.49%-29.66%+8.47% 5.75B
Average +0.37%-1.69%+11.61%+57.49% 14.12B
Weighted average by Cap. +0.42%-1.08%+25.13%+81.52%

Financials

2024 2025
Net sales 5.09M 3.55M 3.12M 2.9M 2.67M 5M 344M 34.67M 13.52M 168M 13.32M 13.04M 582M 1.19M 830K 730K 678K 623K 1.17M 80.34M 8.11M 3.16M 39.18M 3.11M 3.05M 136M
Net income -5.8M -4.04M -3.56M -3.3M -3.04M -5.7M -392M -39.5M -15.41M -191M -15.18M -14.85M -663M -5.94M -4.14M -3.64M -3.39M -3.11M -5.84M -401M -40.49M -15.79M -196M -15.56M -15.22M -679M
Net Debt 759K 529K 465K 432K 398K 746K 51.24M 5.17M 2.02M 24.99M 1.99M 1.94M 86.71M 2.77M 1.93M 1.7M 1.58M 1.45M 2.72M 187M 18.88M 7.36M 91.28M 7.25M 7.1M 317M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
26-07-24 A$0.0120 0.00% 30,408
26-07-23 A$0.0120 0.00% 111,592
26-07-22 A$0.0120 0.00% 339
26-07-21 A$0.0120 0.00% 700,000
26-07-20 A$0.0120 0.00% 250,000

Annual profits - Rate of surprise